Asian News International on MSN5d
Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH
Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...
pharmaphorum6d
Madrigal sees road to approval for NASH drug resmetirom
Although, so far efforts to bring a therapy to market have failed ... a filing in the lead indication of non-cirrhotic NASH with liver fibrosis hinged on a positive readout in MAESTRO-NASH.
Hepion Pharmaceuticals Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion ...
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
pharmaphorum2d
Novartis muscles into NASH fatty liver disease
Some forecasts suggest the market could be worth $30-40 billion ... and is being studied in NASH with advanced fibrosis (scarring) and cirrhosis. LJN452 is Novartis’ most advanced of two ...